Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer.

Autor: Tsujino, Takuya1 (AUTHOR), Tokushige, Satoshi1 (AUTHOR), Komura, Kazumasa1 (AUTHOR) kazumasa.komura@ompu.ac.jp, Fukuokaya, Wataru2 (AUTHOR), Adachi, Takahiro3 (AUTHOR), Hirasawa, Yosuke3 (AUTHOR), Hashimoto, Takeshi3 (AUTHOR), Yoshizawa, Atsuhiko4 (AUTHOR), Saruta, Masanobu4 (AUTHOR), Ohno, Takaya1 (AUTHOR), Nakamori, Keita1 (AUTHOR), Maenosono, Ryoichi1 (AUTHOR), Nishimura, Kazuki1 (AUTHOR), Yamazaki, Shogo1 (AUTHOR), Uchimoto, Taizo1 (AUTHOR), Yanagisawa, Takafumi2 (AUTHOR), Mori, Keiichiro2 (AUTHOR), Urabe, Fumihiko2 (AUTHOR), Tsuzuki, Shunsuke2 (AUTHOR), Iwatani, Kosuke2 (AUTHOR)
Zdroj: Cancer Medicine. Oct2023, Vol. 12 Issue 19, p19414-19422. 9p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje